评估临床试验的载体理论:对生物等价性的应用
1Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.
Journal of cardiovascular development and disease
|July 26, 2024
概括
一种新的基于载体的比较 (VBC) 方法通过评估终点相似性来提高临床试验统计数据. 这种方法提高了统计能力,并减少了在药物开发中招募受试者的需求.
科学领域:
- 生物统计学 生物统计学
- 临床试验方法论 临床试验方法论
- 制药指标 (Pharmacometrics) 是一个指标.
背景情况:
- 当前临床试验的统计分析往往忽略了终点差异,导致诸如多重性和功率降低等问题.
- 这需要更多的科目,并使结果的解释变得复杂.
研究的目的:
- 引入和评估基于载体的比较 (VBC) 方法用于对临床试验终点的统计分析.
- 证明VBC提高统计能力和管理多重性问题的能力.
主要方法:
- 基于矢量比较 (VBC) 方法使用矢量代数来表示临床终点.
- 终点被分解成直角元件,只有独立的 (垂直) 矢量用于统计分析.
- VBC被应用于阿姆洛迪平,伊尔贝沙坦和甲酸的生物等价性研究.
主要成果:
- VBC是一种可复制和易于应用的方法,用于分析临床终点.
- 该方法有效地区分并使用表达不同属性的终点组件.
- 在所有评估的临床特征上,VBC 显示了增加的统计能力,但没有增加 I 型错误率.
结论:
- 基于载体的比较 (VBC) 为临床试验提供了一个新且有效的统计框架.
- 这种方法通过专注于独立的终点组件来提高分析能力和精度.
- VBC在优化临床试验设计和分析方面表现有前途,特别是在制药研究中.
相关概念视频
Bioequivalence: Overview
957
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
957
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Pharmacokinetic Models: Comparison and Selection Criterion
64
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
64
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Volume of Distribution
156
The apparent volume of distribution (Vd) is a crucial pharmacokinetic parameter representing the hypothetical body fluid volume into which a drug disperses. It is calculated based on the total amount of drug in the body (estimated from the administered dose and bioavailability) divided by the plasma drug concentration. The total amount of drug in the body does not directly refer to the dose given but is derived by accounting for absorption, distribution, metabolism, and excretion processes.
156


